Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies - Summary - MDSpire
Advertisement
Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies
To evaluate clinical outcomes following escalation to weekly adalimumab in children with refractory pediatric chronic non-infectious anterior uveitis (pCAU) and to explore the role of serum drug levels and anti-adalimumab antibody titres in guiding treatment decisions, emphasizing their potential impact on treatment efficacy.
Key Findings:
15 paediatric patients were included, with a mean age of 11 years.
66.7% of patients achieved disease control at 3 months post-escalation, indicating a promising response rate.
Most patients had persistent ocular inflammation despite compliance with biweekly adalimumab and concurrent immunosuppressive therapies.
Interpretation:
Weekly adalimumab may be an effective escalation strategy for managing refractory pCAU in children, with a significant proportion achieving disease control, highlighting the need for further research.
Limitations:
Retrospective design limits the strength of evidence and may introduce biases.
Small sample size may affect generalizability of findings.
Conclusion:
Weekly adalimumab dosing shows promise in controlling refractory pCAU, but further studies are needed to confirm these findings and establish broader applicability.
by Amelia Rees, Raheej Khan, Jessy Choi, Clare Nash, Daniel Hawley, Sasa Pockar, Shiao Wei Wong, Guilia Varnier, Vinod Sharma, Alice Chieng, Jane Ashworth
